When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

The clinical strategy of 'saving' the most effective drugs for later lines of therapy may be flawed. Data indicates that 20-30% of patients with metastatic breast cancer do not go on to receive a subsequent line of treatment after progression, arguing for the use of optimal therapies like ADCs earlier in the disease course.

Large-scale SEER database analysis shows that patients with T1A and T1B node-negative triple-negative breast cancer had similar outcomes whether they received chemotherapy or were just observed. This challenges the default use of chemotherapy for all patients with very early-stage TNBC.

Advances like immunotherapy and Antibody-Drug Conjugates (ADCs) in early-stage Triple-Negative Breast Cancer (TNBC) are so effective that fewer patients are relapsing. This success paradoxically makes it harder to enroll patients in trials for metastatic disease, shifting the trial population toward those with de novo metastatic cancer.

In community settings, a majority of Small Cell Lung Cancer patients (50-60%) deteriorate too quickly to receive second-line treatment, compared to 30% in academic centers. This highlights the disease's aggressiveness and the necessity of using the most effective treatments first, as many patients will not get a second chance.

Early clinical trial data for the ADC mirvetuximab shows a response rate of 39% in patients with one to three prior lines of therapy. This rate drops significantly for patients with four or more lines, supporting prioritization of this drug earlier in the platinum-resistant setting.

In metastatic breast cancer, approximately one-third of patients are unable to proceed to a second line of therapy due to disease progression or declining performance status. This high attrition rate argues for using the most effective agents, such as ADCs, in the first-line setting.

Unlike late-stage treatments, therapies for newly diagnosed cancer patients cannot be highly toxic or delay standard care like surgery. This creates a challenging three-week window for a drug to show efficacy, a major constraint that eliminates most potential treatments.

A key lesson in bladder cancer is that patient attrition is rapid between lines of therapy; many who relapse from localized disease never receive effective later-line treatments. This reality provides a strong rationale for moving the most effective therapies, like EV-pembrolizumab, to earlier settings to maximize the number of patients who can benefit.